Latest

AstraZeneca

FDA Approves AstraZeneca’s Durvalumab (IMFINZI): A Paradigm Shift in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma Treatment

27 November 2025
The therapeutic landscape for resectable gastric and gastroesophageal junction adenocarcinoma (GC/GEJC) has undergone a significant transformation with the FDA’s approval of durvalumab (AstraZeneca) on November 25, 2025, for use in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and

Choroidal Neovascularization Market Expected to Experience Rapid Growth During 2025–2034 Driven by Advancements in Anti-VEGF Therapies | DelveInsight

20 November 2025
The choroidal neovascularization therapeutics market is anticipated to grow further, driven by key factors such as the increasing prevalence of the condition, technological advancements, and emerging therapies—including AbbVie and REGENXBIO’s ABBV-RGX-314, Adverum Biotechnologies’ Ixoberogene soroparvovec, Neuracle Genetics’ NG101, and others—over the forecast

Global Pharmaceutical Contract Manufacturing Market Expected to Exceed USD 360 Billion by 2032 | DelveInsight

20 November 2025
The pharmaceutical contract manufacturing market is witnessing robust growth, largely fueled by the increasing prevalence of chronic and infectious diseases. This expansion is further supported by the growing demand for biologics and biopharmaceuticals. Additionally, pharmaceutical and biotechnology companies are actively strengthening their